<DOC>
	<DOCNO>NCT00615056</DOCNO>
	<brief_summary>The study design demonstrate combination AG-013736 either FOLFIRI FOLFOX superior FOLFIRI FOLFOX combination bevacizumab ( Avastin ) delay tumor progression second-line treatment patient metastatic colorectal cancer failure irinotecan oxaliplatin-containing first-line regimen .</brief_summary>
	<brief_title>A Study Combining FOLFOX FOLFIRI With AG-013736 Bevacizumab ( Avastin ) Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically document colorectal cancer plus one following : Failure one prior irinotecan oxaliplatincontaining regimen , Adjuvant refractory irinotecan oxaliplatincontaining regimen . Prior treatment first line metastatic set one regimen Prior irradiation 25 % bone marrow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>